Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-Severe Uncontrolled Asthma

Inclusion Criteria Lead-in PK Cohort: * 18 to 55 years of age inclusive at the time of signing the informed consent at screening Visit 1. * Bodyweight 50 to 120 kg (inclusive) and BMI 18 to 32 kg/m\^2 (inclusive) at screening Visit 1. * Documented asthma diagnosis ≥12 months prior to screening Visit 1. * Able to perform acceptable lung function testing for FEV1 according to American Thoracic Society / European Respiratory Society (ATS/ERS) 2019 acceptability criteria. * Morning pre- bronchodilator (BD) forced expiratory volume (FEV)1 ≥ 40% predicted at screening Visit 1 and Visit 2. * Treated with low dose inhaled corticosteroid plus long-acting β2-agonist (ICS-LABA) or medium-high dose ICS alone or in combination with LABA at a stable dose for at least 3 months prior to screening Visit 1. Also, treatment with additional asthma controller therapies (eg, LAMA) at a stable dose ≥ 3 months prior to screening Visit 1 is allowed. * Participant's influenza/pneumonia vaccination is up to date as per local guidelines prior to Visit 2. General Inclusion Criteria for Part 1: * Body weight ≥ 40 kg and body mass index (BMI) \< 35 kg/m\^2. * Documented history of ≥ 1 severe asthma exacerbation within 1 year prior to screening Visit 1. * Able to perform acceptable lung function testing for FEV1 according to ATS/ERS 2019 acceptability criteria. * Morning pre-BD FEV1 between ≥ 40% and ≤ 85% predicted at screening Visit 1 and Visit 3. * An Asthma Control Questionnaire (ACQ)-6 score ≥ 1.5 …